Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06948318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06948318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Recruiting
Start date
August 14, 2025
Completion date
July 29, 2029
Enrollment
150 (estimated)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenic purpura (itp)